An experimental electric comb called Detangle regrew nearly 100% of shaved hair on mice in 28 days, outperforming minoxidil’s roughly 70%, in a study by Beihang University researchers published this month in Nature Communications.
No human testing has yet occurred.
For the up to 80% of men affected by male-pattern baldness across their lifetimes, that gap between mice and humans is the entire story. The device, detailed in a paper led by Feng Liu and colleagues and published on November 3, remains a proof of concept. Human clinical trials have not been scheduled.
Comb tested only in mice, not humans
- The comb works only in mice so far; there is no evidence it will regrow hair on a human scalp.
- It combines electrical pulses with two experimental gene-based therapies — neither is an approved drug.
- Existing treatments like minoxidil and finasteride remain the options while this technology moves through testing.
How Detangle pushes treatment nine times deeper
Pattern hair loss begins beneath the skin, where follicles shrink under the influence of dihydrotestosterone, or DHT, and produce progressively finer hairs. Topical treatments struggle to reach those follicles through the skin’s barrier.
Detangle’s teeth come in two heights, embedded with electrodes and drug-loaded reservoirs — a design the team says was inspired by the animated film Tangled. When drawn across skin, the longer teeth create furrows that let a pulsed electric field reach roughly nine times deeper than conventional topical application, according to the study. The field is 2.63 times stronger than one generated by teeth in a straight row.
The pulses also drive the loaded molecules into cells through electroporation, which briefly makes cell membranes more permeable. Two experimental treatments do the therapeutic work: a VEGFA plasmid that promotes blood-vessel growth around follicles, and SRD5A2 siRNA, which suppresses the enzyme that produces DHT.

The numbers behind the “nearly 100%” claim
Researchers induced hair loss in male mice with testosterone, then treated shaved patches once every three days for 28 days. The full system reached about 97.85% hair coverage. Outlets differ slightly in rounding: coverage describes “nearly 100%” versus roughly 70% for minoxidil, while reports give the fuller breakdown.
| Treatment | Hair regrowth after 28 days (mice) |
|---|---|
| Untreated control | ~1% |
| Electrostimulation alone | ~40% |
| Finasteride (oral) | ~50% |
| Minoxidil (topical) | ~70% |
| Comb + SRD5A2 siRNA | ~85% |
| Comb + VEGFA plasmid | ~90% |
| Full system (electricity + both molecules) | ~97.85% |
That table exposes a nuance the headlines flatten. Electrostimulation alone beat no treatment but trailed both drugs — meaning the drug-delivery step accounts for much of the gain, a point coverage noted the study does not test directly.
“This approach accelerates hair growth nearly 100 percent within a month in the AGA mouse model, surpassing the outcomes achievable with conventional oral or external medications,” the researchers wrote in the paper.
The study also found the device increased follicle numbers and improved blood flow to treated skin, findings the authors attribute to getting therapeutic molecules deep into the follicle region.

Why mouse results rarely transfer cleanly
The model matters. Researchers applied testosterone directly to shaved mouse skin for 28 days — an induced condition that does not match how pattern hair loss develops in people over years, as reporting noted. Human androgenetic alopecia progresses gradually under genetic and hormonal influences that a mouse model only approximates.
The gene-based payloads add another layer of uncertainty. A plasmid and an siRNA are experimental biological treatments, not established medicines, and each would face its own safety review before any combined device could reach patients.
A comb with electrified teeth regrew nearly all lost hair on balding skin in a month. The device, called Detangle, was built by engineers at Beihang University in Beijing and described in Nature Communications. Its teeth carry tiny electrodes set at different heights, plus… pic.twitter.com/Fp6qpw23Ax
Regulatory distance is considerable. A device-plus-drug combination would need to clear safety and efficacy trials in humans before regulators could consider approval; reporting noted observers expect considerable time before human clinical data are secured. The researchers hope the technology could eventually serve the roughly 1.5 billion people worldwide estimated to live with the condition.
Where current treatments stand
Minoxidil can slow loss and encourage regrowth, but results vary. While effective, this treatment can be invasive, painful and costly.

Finasteride works in early-stage baldness. Hair transplantation, which moves follicles from areas resistant to loss, is effective but invasive, painful and costly.
Device unavailable; see doctor for sudden hair loss
Detangle is not a product anyone can buy or use; it exists only in a laboratory. Anyone experiencing sudden or patchy hair loss, shedding after illness or medication changes, or scalp inflammation should see a physician or healthcare provider, since these patterns can signal treatable conditions distinct from androgenetic alopecia. Patients weighing minoxidil or finasteride should discuss side effects and contraindications with a clinician before starting either.
A measured next step
The device’s genuine innovation is delivery: a familiar object that places electrodes and therapeutic payloads precisely where follicles sit. Whether that translates from mouse backs to human scalps — and whether any gains last — awaits trials that have not yet begun. The study, Combing-triggered electrostimulation synchronizing deep delivery for rapid hair regrowth in androgenetic alopecia, was published in Nature Communications on November 3.
References
- Liu F, Yao F, Sun H, et al. “Combing-triggered electrostimulation synchronizing deep delivery for rapid hair regrowth in androgenetic alopecia.” Nature Communications, 2026. doi.org/10.1038/s41467-026-79122-3
- MedlinePlus Genetics: Androgenetic alopecia
- MedlinePlus Genetics: SRD5A2 gene
- “Scientists invent electric comb that restores hair growth ‘nearly 100%'”
- Coverage of the Nature Communications study, November 2026